UNSPSC 51183309: Saxagliptin monohydrate

This classification denotes an anti-diabetic agent C18H25N3O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9GB927LAJW, chemically known as (1s,3s,5s)-2-((2s)-amino(3-hydroxytricyclo(3.3.1.1(sup 3,7))dec-1-yl)acetyl)2-azabicyclo(3.1.0)hexane-3-carbonitrile monohydrate, but more generally known as saxagliptin monohydrate, which bears US NIH Compound Identifier 53297473. Most nations, for tariff and trade purposes, schedule saxagliptin monohydrate under HS 29339990 and SITC 51577.

As of Q4 2014, SAXAGLIPTIN MONOHYDRATE remains US FDA's Preferred Term for this commodity. SMILES: C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H]([C@]34C[C@@H]5CC(C3)C[C@@](C5)(C4)O)N.O.

UNSPSC 51183309 Saxagliptin monohydrate is a Commodity code representing a specific diabetes medication in the pharmaceutical supply chain. State and local governments procure this product primarily through cooperative purchasing consortiums that establish master contracts for generic and branded pharmaceuticals to serve health departments, correctional facilities, public health clinics, and other state and local care settings. The work involves manufacturer participation in multi-state pharmaceutical aggregation programs where vendors commit pricing, supply chain compliance, and regulatory certification in exchange for volume distribution through authorized pharmaceutical wholesalers. Issuing bodies are typically state health departments and multistate cooperative purchasing organizations such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which coordinate procurement on behalf of participating state and local agencies across multiple jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026, with a response deadline of March 26, 2026, for a master contract covering generic multi-source pharmaceuticals and OTC products including saxagliptin monohydrate across participating states and local government facilities, including Oregon. The solicitation requires vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with products available by May 15, 2026, and contract effectiveness July 1, 2026. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and 5 percent each on compliance with administrative data format requirements, EDI capability, and acceptance of a 3 percent administrative fee. Vendors must certify cGMP and DSCSA compliance, maintain relationships with at least two of the three authorized wholesalers with chargeback systems in place, carry professional liability insurance of $2 million, and demonstrate pricing flexibility through flat price, net price, or WAC-minus structures over a two-year initial term with optional extensions through June 30, 2028.